Lehne's Pharmacology for Nursing Care

Key differences between 9th and 8th editions

• Time lapse between current and previous publications: 3 years (2015 vs 2012).
• Lehne's text was first published in 1990.
• New authors Jacqueline Burchum and Laura Rosenthal.
• Safety Alerts point to important drug safety issues, such as contraindications, drug interactions, side effects.
• The Ninth Edition presents new drugs and essential new drug formulations, including:
• Dapagliflozin (Farxiga, Forxiga) -- a sodium glucose cotransporter type 2 (SGLT-2) inhibitor for type 2 diabetes.
• Albiglutide (Eperzan, Tanzeum) -- a glucagon-like peptide-1 agonist for type 2 diabetes.
• Alogliptin (Nesina, Vipidia) -- DPP-4 inhibitor, anti-diabetic medication.
• Levomilnacipran (Fetzima) -- a selective serotonin and norepinephrine reuptake inhibitor antidepressant
• Apixaban (Eliquis) -- direct factor Xa inhibitor.
• Lorcaserin (Belviq) -- serotonin 2C receptor agonist for weight management.
• Avanafil (Stendr) -- a novel PDE-5 inhibitor for erectile dysfunction.
• Bedaquiline (Sirturo) -- anti-tuberculosis drug, multi-drug resistant tuberculosis.
• Former chapter 50 "Prophylaxis of Coronary Heart Disease" has been relabeled to "Prophylaxis of Atherosclerotic Cardiovascular Disease".
• Former chapter 108 "Dietary Supplements" has been relabeled to "Complementary and Alternative Therapy".
• The 9th Pharmacology for Nursing Care provides Canadian drug names.